Jennifer Jarrett bought $253k of DMRA
Director, President and CEO at Damora Therapeutics, Inc.. 12,500 shares at an average of $20.23, traded Sep 25, 2026, filed Sep 28, 2026.
Score components
- +25RoleCEO
- +13Trade size$253k at market
- 0Relative to holdingsHoldings up 2.5%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-403355, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | POpen-market purchase Ordinary Shares | +12,500 | $20.23 | $253k | 512,500 | 15 d ago |
Related signals
Other insiders at Damora Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | DMRAsell Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $7,345 245 shares | -10% | |
| 27Weak | Damora Therapeutics, Inc. | Lori Firmani Chief Financial Officer | $2,890 135 shares | -13% | |
| 20Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $5,452 255 shares | -12% | |
| 30Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $15k 700 shares | -13% | |
| 27Weak | Damora Therapeutics, Inc. | Lori Firmani Interim CFO | $498 147 shares | -18% | |
| 20Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $881 260 shares | -15% | |
| 30Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $2,484 735 shares | -15% | |
| 32Weak | Damora Therapeutics, Inc. | Lori Firmani Interim CFO | $1,469 261 shares | -36% | |
| 35Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $7,510 1,341 shares | -28% | |
| 25Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $2,638 471 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.